Controversies in surgical management of advanced ovarian cancer (stage III-IV)

European Journal of Gynaecological Oncology

Volumn 21, Issue 5, 2000, Pages 449-460

  Makar, A Ph ^a   Kisic, J ^a   Trope C G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LYMPHADENECTOMY; MORBIDITY; OVARY CANCER; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURGICAL APPROACH;

FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 0034508704     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. FIGO annual report on the the results of treatment in gynecological cancer
2. Improved prognosis of ovarian cancer in the Netherlands during the period 1975-1985. A registry based study
3. Factors influencing survival in carcinoma of the ovary
4. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases
5. Trends in the incidence of ovarian cancer and borderline tumours in Norway
6. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993
7. Surgery at the time of diagnosis in ovarian cancer
8. Principles of chemotherapy
9. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
10. Primary surgery for ovarian carcinoma
11. Primary cytoreduction
12. The role of surgery in the management of ovarian cancer: Primary and interval cytoreductive surgery
13. Surgery in the treatment of patients with advanced ovarian cancer
14. The changing prognosis and treatment in cancer of the ovary: A report of 235 patients with primary ovarian carcinoma 1952-1961
15. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
16. Tumor reduction surgery and long term survival in advanced ovarian cancer: A DACOVA study
17. The treatment of advanced ovarian carcinoma (1): Clinical variables associated with prognosis
18. Surgery in advanced ovarian carcinoma: Is there proof to show the benefit
19. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
20. The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO stage III ovarian cancer
21. The management of diaphragmatic lesions in ovarian carcinoma
22. Carbon dioxide laser vaporization of diaphragmatic metastases for cytoreduction of ovarian epithelial cancer
23. Reverse hysterocolposigmoidectomy (RHCS) for resection of panpelvic tumors
24. Modified posterior exentration for ovarian cancer
25. Pelvic lymphadenctomy in operative treatment of ovarian cancer
26. Patterns of pelvic and para-aortic lymph node involvement in ovarian cancer
27. Management of advanced ovarian cancer
28. Lymph node metastasis and retroperitoneal lymphadenctomy in ovarian cancer
29. Pelvic and para-aortic lymphadenectomy in cancer of the ovary
30. Aortic lymph node metastases in early ovarian cancer
31. Incidence of para-aortic and pelvic node metastasis in epithelial carcinoma of the ovary
32. Prognostic significance of morphology of tumor and retroperitoneal lymph nodes in epithelial carcinoma of the ovary
33. Para-aortal lymph node dissection in 20 cases of primary epithelial ovary carcinoma. Stage I (FIGO): Influence on staging
34. Para-aortic lymphadenectomy in gynecologic malignancies confined to the pelvis
35. Retroperitoneal metastatic spread of ovarian cancer
36. Pelvic and para-aortic lymph node positivity in the ovarian carcinoma: Its prognostic significance
37. Debulking of pelvic and paraaortic lymph node metastases in ovarian cancer with the cavitron ultrasonic surgical aspirator
38. The influence of tumor distribution number and size after optimal cytoreductive surgery for epithelial ovarian cancer
39. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
40. Electrosurgical debulking of ovarian cancer: A new technique using the argon beam coagulator
41. Peritoneal implant elimination cytoreductive surgery for ovarian cancer. The impact on survival
42. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study
43. Primary cytoreductive surgery for epithelial ovarian cancer
44. Surgical management of advanced ovarian cancer
45. Cytoreduction in ovarian cancer: Achievability and results
46. Primary surgical therapy of ovarian cancer: How much and when
47. Intestinal obstruction in advanced ovarian cancer: What does the patient want?
48. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer
49. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma
50. Stage IV ovarian cancer: Impact of surgical debulking
51. Effect of surgical debulking on survival in stage IV ovarian cancer
52. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer
53. Treatment of advanced ovarian carcinoma in the elderly
54. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary
55. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary
56. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis
57. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy
58. Predictability of the survival of patients with advanced ovarian cancer
59. "Surgery in gynecologic malignancy from quality to quantity of life". Review
60. The effect of chemotherapy on lymph node metastases in ovarian cancer
61. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma
62. Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage non-semimatous testicular cancer
63. Debulking surgery: Does it increase the quality of survival
64. Management of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery in independent determinant of prognosis
65. Primary surgery in ovarian cancer: Current Opinions
66. National survey of ovarian carcinomas 5. The impact of physicians speciality on patients survival
67. Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity
68. Morbidity and mortality associated with primary and repeat operations for ovarian cancer
69. Unsettled questions regarding ovarian cancer
70. The potential for optimal (<=2cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center. A prospective study
71. Intervention debulking surgery in advanced epithelial ovarian cancer
72. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer: An EORTC Gynecological Cancer Cooperative Group Study
73. Proceedings of the International Society of Gynecologic Cancer
74. The feasibility of open laparoscopy in gynecological oncologic patients
75. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with log (relative risk)) as main objectives
76. Surgery during chemotherapy and at relapse of ovarian cancer
77. Second thoughts about second-look laparotomy in advanced ovarian cancer
78. A review of second-look laparotomy for ovarian cancer
79. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma
80. Microscopic disease at second-look laparotomy in advanced ovarian cancer
81. Second-look laparotomy and salvage therapy: A research modality only?
82. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma
83. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy
84. Second-look laparotomy in the management of gynecologic malignancy
85. Second-look laparotomy after chemotherapy in the management of ovarian malignancy
86. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer
87. Second-look operations in ovarian cancer
88. CA125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer
89. Evaluation of debulking surgery at second-look laparotomy
90. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
91. Secondary cytoreductive surgery in ovarian cancer
92. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
93. Follow-up after primary therapy: Management of the symptomatic patient surgery
94. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response
95. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian cancer
96. Influence of secondary cytoreduction at the time of second-look laparotomy on survival of patients with ovarian cancer
97. "Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer". May 4-7, 1995, Glasgow, UK
98. Palliative surgery for intestinal obstruction in advanced ovarian cancer
99. Conservative management of small bowel obstruction
100. Surgical management of bowel obstruction in advanced ovarian carcinoma
101. Somatostatin as adjuvant therapy in the management of obstructive ileus